Ajudes rebudes: Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol) i Astra ZenecaObjectives:To assess trends in prescribing practices of antidiabetic agents and glycaemic control in patients with type 2 diabetes mellitus (T2DM). Design: Cross-sectional analysis using yearly clinical data and antidiabetic treatments prescribed obtained from an electronic population database. Setting: Primary healthcare centres, including the entire population attended by the Institut Català de la Salut in Catalonia, Spain, from 2007 to 2013.Participants: Patients aged 31-90 years with a diagnosis of T2DM. Results: The number of registered patients with T2DM in the database was 257 072 in 2007, increasing up to 343 969 in 201...
Victoria Higgins, James Piercy, Adam Roughley, Gary Milligan, Andrea Leith, ...
AIM: To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 d...
Objective: To assess the uptake of second line antihyperglycaemic drugs among patients with type 2 d...
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control i...
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control i...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, an...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, an...
Aim: To describe population‐level time trends in prescribing patterns of type 2 diabetes therapy, an...
Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recent...
BACKGROUND: Type 2 diabetes is an important cause of morbidity and mortality. Its prevalence appears...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, ...
Ajuda rebuda: GlaxoSmithKlineSeveral glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) hav...
Altres ajuts: Institut Universitari d'Investigació en Atenció Primària Jordi GolAltres ajuts: MSD Sp...
Altres ajuts: Institut Universitari d'Investigació en Atenció Primària Jordi GolAltres ajuts: MSD Sp...
This is the author accepted manuscript. The final version is available on open access from Wiley via...
Victoria Higgins, James Piercy, Adam Roughley, Gary Milligan, Andrea Leith, ...
AIM: To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 d...
Objective: To assess the uptake of second line antihyperglycaemic drugs among patients with type 2 d...
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control i...
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control i...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, an...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, an...
Aim: To describe population‐level time trends in prescribing patterns of type 2 diabetes therapy, an...
Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recent...
BACKGROUND: Type 2 diabetes is an important cause of morbidity and mortality. Its prevalence appears...
Aim: To describe population-level time trends in prescribing patterns of type 2 diabetes therapy, ...
Ajuda rebuda: GlaxoSmithKlineSeveral glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) hav...
Altres ajuts: Institut Universitari d'Investigació en Atenció Primària Jordi GolAltres ajuts: MSD Sp...
Altres ajuts: Institut Universitari d'Investigació en Atenció Primària Jordi GolAltres ajuts: MSD Sp...
This is the author accepted manuscript. The final version is available on open access from Wiley via...
Victoria Higgins, James Piercy, Adam Roughley, Gary Milligan, Andrea Leith, ...
AIM: To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 d...
Objective: To assess the uptake of second line antihyperglycaemic drugs among patients with type 2 d...